Ivan Barrera

Rationale for the utilization of biological targeted agents (bTAs) in the treatment of metastatic colorectal cancer (mCRC), single tertiary cancer center experience.

Ivan Barrera, Yahia Abdelali Lakehal, Tomas Kavan, Petr Kavan

e15589 Background: Worldwide treatment for 1st line (1LTx) mCRC included doublet or triple chemotherapy with or without bTAs. In Quebec, the anti-EGFR therapy (panitumumab or cetuximab) was only recently approved in this setting for patients RAS WT, Bevacizumab (B) not eligible. In …

ca (code pays fourni par la source)

Genetic reduction of cilium length by targeting intraflagellar transport 88 protein impedes kidney and liver cyst formation in mouse models of autosomal polycystic kidney disease

Lina Shao, Wassim El-Jouni, Fanwu Kong, Janani Ramesh et autres

us, cn (code pays fourni par la source)

First-line drug selection versus sequential treatment in advanced pancreatic cancer: Does it really matter? Multi-institutional Canadian perspective.

Ivan Barrera, Neha Papneja, Jill J. Ranger, Abhishek Papneja et autres

673 Background: Folfirinox (FFX) and Gemcitabine with nab-Paclitaxel (GN) are both proven to be superior to Gemcitabine (G) in the first line treatment (1LTx) for advanced pancreatic cancer (APC). Yet, the optimal 1LTx selection nor sequential Tx (ST) has not been fully …

ca (code pays fourni par la source)

Adjuvant Therapy for Stages II and III Colon Cancer: Risk Stratification, Treatment Duration, and Future Directions

Uri Bender, Young Soo Rho, Ivan Barrera, S. Aghajanyan et autres

Background: To date, the role of adjuvant systemic therapy in stages ii and iii colon cancer remains a topic of interest and debate. The objective of the present review was to assess the most recent data, specifically addressing methods of risk stratification, …

ca, us (code pays fourni par la source)

Outcomes of first-line FOLFIRINOX (FFX) versus gemcitabine and nab-paclitaxel (GN) in patients with advanced pancreatic cancer: Multi-Institutional Canadian sites experience

Neha Papneja, Shahid Ahmed, P. Mondal, Ivan Barrera et autres

Treatment sequencing in MPC, insights from a 3˚ care center.

Ivan Barrera, Jill J. Ranger, Nooshin Roofigari, Richard Dalfen et autres

400 Background: Since 2011, options for treatment of metastatic pancreatic cancer (mPC) have improved with the use of nab-paclitaxel plus gemcitabine (n-PGEM) or FOLFIRINOX (FFX) as first line treatments (1LTx). In 2016, Nanoliposomal irinotecan plus 5FU (nal-IRI-5FU) demonstrated efficacy in 2LTx. Yet, …

ca (code pays fourni par la source)

A multi-institutional randomized phase II study on the timing of oxaliplatin plus 5-fluorouracil (FOLFOX) for patients (pts) with operable stage III rectal cancer: The KIR study

Petr Kavan, Ivan Barrera, Laurent Azoulay, A.-G. Martin et autres

Background: Recent randomized studies have shown low compliance to adjuvant chemotherapy in stage III rectal cancer pts who received preoperative combined chemotherapy and external beam radiation (CT/EBRT) with total mesorectal excision (TME surgery). We examined whether giving part of the chemotherapy prior …

ca (code pays fourni par la source)

Metastatic site of loss of oncologic control in colorectal cancer patients.

Charles Vincent Rajadurai, Steph A. Pang, Jill J. Ranger, Ivan Barrera et autres

e15568 Background: Mortality related to colorectal cancer (CRC) is largely due to regional metastasis to portal/mesenteric lymph nodes and peritoneum as well as distant metastasis to vital organs such as lung, liver, bone and brain. Approximately 50% of patients diagnosed with CRC …

ca (code pays fourni par la source)

Assessing physician adherence to clinical practice guidelines in the management of cancer-associated venous thromboembolism: a retrospective analysis from a tertiary care centre in Canada

Mitchell A. Bernstein, Ivan Barrera, Jill J. Ranger, Henry Rho et autres

ca (code pays fourni par la source)

Folfirinox (FFX) versus gemcitabine with nab‐paclitaxel (GNP) in the first line treatment (1LTx) of metastatic pancreatic cancer (mPC): A tertiary center experience.

Ivan Barrera, Sabina Hamalova, Jill J. Ranger, Henry Rho et autres

414 Background: The efficacy of FFX and GNP as 1LTx of mPC were established in phase 3 trials against Gemcitabine alone. However, no head‐to‐head trial has been performed. This analysis was conducted to compare the use of the two regimens in the …

ca (code pays fourni par la source)

A patient-centered approach to the re-development of supportive care services for oncology adolescent and young adult (AYA) patients (pt(s)) across McGill University hospitals (Rossy Cancer Network-RCN)

Petr Kavan, Roy A Fox, G. Raskovic, Ivan Barrera et autres

ca (code pays fourni par la source)

Prognostic value of neutrophil-lymphocyte ratio in first line treatment for metastatic pancreatic adenocarcinoma

Young Soo Rho, Jill J. Ranger, Sabina Hamalova, Ivan Barrera et autres

us, ca (code pays fourni par la source)